81results about How to "Delayed healing" patented technology

Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160–400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5–20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.

The invention discloses an absorbable haemostatic material of a modified starch and a preparation method thereof. The haemostatic material is etherified modified starch or a composition which is formed by one or two or more than two of the etherified modified starch, cross-linked and composite modified starch, with a molecular weight of 15,000 to 2,000,000, a grain diameter of 10-1000Mu m and a water absorbency of 1 time to 100 times. The modified starch absorbable haemostatic material has the advantages that: the haemostatic material with biocompatibility is directly applied to bloody surface of wound to stop bleeding immediately, obviously increase the water absorbency and the water absorbing speed and have more viscosity and viscidity, thereby simultaneously blocking up damaged tissues and blood vessels while stopping bleeding. The haemostatic material is easy to swell or dissolve in water and after stopping bleeding, normal saline is used for washing to eliminate the haemostatic material not participating in stopping bleeding, thus reducing residues in the body, being beneficial to wound healing, and avoiding pains caused by unclosing pledget and bandage. The haemostatic material has the physical and chemical properties of stability, difficult decomposition, long guarantee period, convenient storage, high pressure resistance, low pressure resistance, high temperature resistance, low temperature resistance and difficult change.

A warming system, mounted to the foot of a bed, warms a person's lower extremities by directing air into the space between the mattress and overlaying blankets. A blower directs air into an elongated distribution chamber having many tiny exit apertures. The chamber is mounted at the foot of the bed, so that air exiting the apertures warms the person's feet. For maximum thermal transfer, the chamber is placed under the sheet and any blankets, but above the mattress cover and fitted sheet. The chamber may be implemented by a length of open cell foam, a hollow manifold with many punctures or other tiny distribution apertures, collapsible pocket, etc. While the person is lying on the bed beneath the blankets, with feet proximate the foot of the bed, the blower directs temperature-regulated air into the chamber and through the exit apertures, thereby warming the person's feet. A temperature regulator ensures a normothermic air temperature (or alternatively, hyperthermic air temperature.) Thus, the invention helps relieve or prevent “cold feet” by directing normothermic air at a person's lower extremities. Additionally, by applying heat to the feet and legs, the invention encourages blood flow by virtue of sympathetic vasodilation and local temperature-mediated vasodilation. The invention is also believed to prevent some leg and foot ulcers from forming by maintaining the lower extremity at a near normal temperature during sleep.

An electrosurgical system comprises a radio frequency generator (1), an electrosurgical instrument (E1), and a fluid enclosure (42). The generator (1) has a radio frequency output for delivery of power to the electrosurgical instrument (E1) when immersed in an electrically-conductive fluid. The electrosurgical instrument (E1) has an electrode assembly (32) at the distal end thereof, the electrode assembly comprising a tissue treatment electrode (34), and a return electrode (38) axially spaced therefrom in such a manner as to define, in use, a conductive fluid path that completes an electrical circuit between the tissue treatment electrode and the return electrode. The fluid enclosure (42) is adapted to surround an operation site on the skin of a patient or an incision leading to a cavity surgically created within the patient's body. The fluid enclosure (42) includes sealing means (44) for sealing against the patient's tissue, and the fluid enclosure includes at least one port (50a, 52a) through which the electrosurgical (E1) is insertable, and through which the electrically-conductive fluid can enter and / or leave the enclosure.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

A non-invasive tissue oxygenation system for accelerating the healing of damaged tissue and to promote tissue viability is disclosed herein. The system is comprised of a lightweight portable electrochemical oxygen concentrator, a power management system, microprocessors, memory, a pressure sensing system, an optional temperature monitoring system, oxygen flow rate / oxygen partial pressure monitoring and control system, a display screen and key pad navigation controls as a means of providing continuous variably controlled low dosages of oxygen to a wound site and monitoring the healing process. A kink resistant oxygen delivery tubing, whereby the proximal end is removably connected to the device and the distal end with holes or a flexible, flat, oxygen-permeable tape is positioned at or near the wound bed as a means of applying near 100% pure oxygen to the wound site. The distal end of the tube is in communication with the electrochemical oxygen concentrator and wound monitoring system to communicate oxygen partial pressure and, where appropriate, temperature information. A moisture absorbent dressing is positioned over the distal end of the tubing at the wound site and a reduced moisture vapor permeable dressing system is positioned whereby covering the moisture absorbent dressing, distal end of tubing and wound site creating a restricted or occluded airflow enclosure. The restricted airflow enclosure allows the out-of-the-way control and display unit to provide a controlled hyperoxia and hypoxia wound site for accelerated wound healing.

A wound treatment system includes a housing. A processor is located in the housing. A pressure monitoring system is coupled to the processor. A power delivery system is located in the housing and coupled to the processor. An oxygen concentrator is located in the housing and coupled to the power delivery system. The oxygen concentrator includes a plurality of oxygen outlets. The processor is configured to receive pressure information from the pressure monitoring system that is indicative of a pressure in a restricted airflow enclosure provided by a dressing and located adjacent a wound site; and use the pressure information to control the power provided from the power delivery system to the oxygen concentrator in order to control an oxygen flow created by the oxygen concentrator and provided through one of the plurality of oxygen outlets to the restricted airflow enclosure.

In an embodiment of the present invention, a nutraceutical formula comprising a combination of chromium, zinc, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll, and L-arginine combined synergistically to enhance wound healing in mammals not suffering from diabetes.